CACI (CACI) Q3 2026 earnings review
ARKA Deal Closes: Revenue Gets a Boost, But Debt Bites the Bottom Line
CACI's Q3 results show a company executing well on its top line while absorbing the financial weight of its largest acquisition to date. Revenue grew 8.5% YoY, reaccelerating from Q2's 5.7%, aided by 6.8% organic growth and the mid-quarter closing of the $2.6B ARKA Group deal. Operating leverage is shining through: EBITDA margins hit a record 12.3%, up from 11.7% a year ago, even after absorbing $17.4M in ARKA transaction expenses. However, the updated FY26 guidance reveals a trade-off. While management raised the revenue outlook (adding ARKA's ~$150M contribution) and bumped up EBITDA margin targets, they quietly lowered Adjusted Net Income and Adjusted EPS guidance. The debt taken on to fund the all-cash ARKA purchase is dragging down near-term earnings, making rapid deleveraging the most critical metric to watch over the next six quarters.
🐂 Bull Case
EBITDA margin reached 12.3%, up 60 basis points YoY. This profitability jump proves management's strategy of shifting the mix toward higher-margin software and technology is working, completely offsetting ARKA transaction costs.
Free Cash Flow grew nearly 18% YoY to $221.4M in the quarter. The company reaffirmed its massive $725M+ target for the full year, providing the exact liquidity needed to quickly pay down ARKA-related debt.
🐻 Bear Case
Despite raising top-line and operating profit guidance, management was forced to cut Adjusted EPS guidance by roughly $0.55 at the midpoint. Interest expense jumped 15.8% YoY this quarter and will be significantly heavier in Q4 with a full quarter of ARKA debt on the books.
Contract awards of $2.2B yielded a quarterly book-to-bill ratio of 0.94x. Following Q2's weak 0.65x, the company needs a massive Q4 to replenish its short-term pipeline, despite a healthy long-term backlog.
⚖️ Verdict: ⚪
Neutral. Operationally, CACI is firing on all cylinders with expanding margins and excellent cash conversion. However, the strategic pivot into space via the ARKA acquisition has fundamentally altered the near-term risk profile, replacing EPS growth with a heavy debt burden that will take multiple quarters to digest.
Key Themes
Technology Mix Shift Driving Structural Margin Expansion
CACI's deliberate pivot from a traditional expertise-based contractor to a technology-first provider is the primary engine of its margin expansion. Technology revenue grew 11.2% YoY in Q3 (reaching $1.33B), vastly outpacing the Expertise segment's 5.2% growth. Technology now accounts for 56.5% of total revenue, up from 55.1% a year ago. This mix shift is directly responsible for the EBITDA margin expanding to 12.3% and management's confidence in raising the full-year margin outlook.
The True Cost of ARKA: EPS Guidance Cut
While CACI champions the strategic benefits of the $2.6B ARKA Group acquisition (electro-optical/infrared capabilities and space expansion), the immediate financial reality is a hit to earnings. Management raised FY26 Revenue and EBITDA margin guidance but simultaneously lowered Adjusted Net Income guidance from a midpoint of $637.5M to $622.5M. This disconnect perfectly illustrates the heavy debt load required to finance the all-cash deal, with interest expenses effectively wiping out the operating profit ARKA brings in the near term.
Spectral Program Reaches Milestone C
CACI achieved a critical inflection point on its Spectral program, completing Navy reviews to reach Milestone C. This transitions the electronic warfare (EW) technology into low-rate initial production (LRIP) and deployment. Moving from development to production on software-defined EW systems is the exact playbook CACI outlined to accelerate high-margin hardware/software hybrid sales.
Sub-1.0x Book-to-Bill Trend
For the second consecutive quarter, contract awards failed to keep pace with revenue. Q3 awards of $2.2B (against $2.35B in revenue) equates to a ~0.94x book-to-bill ratio. Management previously blamed Q2's weak 0.65x ratio on government shutdown timing. With Q3 remaining under 1.0x, it raises questions about whether the delay is purely administrative or if the pipeline conversion is structurally slowing down.
Other KPIs
Accelerating. Up from 11.8% in 26Q2 and 11.7% in 25Q3. This is an exceptional print, especially considering it includes $17.4M in ARKA transaction expenses. If those expenses were excluded, underlying operational margins would have been even stronger, demonstrating excellent indirect cost control.
Up 19.0% YoY, significantly outpacing the 6.4% growth in Total Backlog ($33.4B). This provides excellent near-term revenue visibility and limits downside risk, showing that while new awards have been lumpy, the customer is actively funding existing mandates.
Up 15.8% YoY. This only captures the final three weeks of March following the ARKA close (March 9, 2026). Expect this number to jump significantly in Q4 as a full quarter of the new debt hits the income statement, keeping pressure on net margins.
Guidance
Accelerating. Raised from the prior $9.3 - $9.5B range. The new guidance explicitly includes approximately $150M from the ARKA acquisition. Adjusting for ARKA, organic revenue expectations remain essentially unchanged or slightly higher at the midpoint.
Decelerating. Lowered from the prior $28.25 - $28.92 range. Despite the revenue and margin bump, the midpoint dropped by roughly $0.55 per share. This directly reflects the increased interest expense burden and transaction friction associated with the $2.6B all-cash ARKA purchase.
Accelerating. Raised from 11.7% - 11.8%. Reflects stronger-than-expected performance in the organic technology portfolio and rigorous indirect cost management, helping partially offset the bottom-line drag from new debt.
Stable. Reaffirmed despite the absorption of ARKA transaction costs. The reaffirmation is critical because achieving this $725M+ target is the required mechanism for CACI to execute its plan of rapidly deleveraging back to the 'low 3s' within six quarters.
Key Questions
ARKA Organic Growth Profile
You've guided to ~$150M in revenue contribution from ARKA for the remainder of the year. What is the organic growth assumption for the ARKA business going into FY27, and how does its margin profile currently compare to the corporate average?
Pace of Deleveraging
With leverage expected to spike to ~4.3x post-ARKA, can you walk us through the specific capital allocation priorities for the next 12-18 months? Are share repurchases completely paused until you hit your target in the low 3s?
Book-to-Bill Cadence
We've now seen two consecutive quarters of book-to-bill below 1.0x. How much of this is lingering administrative friction from prior shutdown concerns versus a structural shift in the pace of government procurement?